Breast Cancer Clinical Trial
Official title:
Vitamin D, Weight Loss, and Breast Cancer Biomarkers
Experimental and human data suggests that vitamin D could protect against breast cancer. Overweight/obese individuals are at increased risk of low vitamin D levels. Vitamin D may reduce production of fat tissue, thereby reducing weight gain, which would result in lower levels of adipose-derived hormones and other breast cancer risk factors.The purpose of this study is to test the effect of vitamin D supplementation on the response to a weight loss (diet + exercise) intervention and select breast cancer risk factors in overweight and obese postmenopausal women with low blood vitamin D levels.
Objective: To test the incremental effect of vitamin D supplementation (2000 IU/day) in 228
overweight and obese postmenopausal women with low blood vitamin D levels on response to a
weight loss (diet + exercise) intervention in a double-blind placebo-controlled clinical
trial.
Primary Aim:
• Determine the effects of 12-months vitamin D supplementation vs. placebo on weight loss in
women following a weight loss diet and exercise program.
Secondary Aims:
- Determine the effects of 12-months vitamin D vs. placebo on blood biomarkers associated
with increased breast cancer risk (insulin, glucose, CRP).
- Test 12-months vitamin D effects on muscle strength as measured by 1RM leg press and
bench press in women undergoing weight loss.
- Test the effect of 12-month vitamin D supplementation on effects on quality of life
(QOL) in women undergoing weight loss.
Additional Aims:
- In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs.
placebo on breast epithelial cell cytomorphology (quantified by the Masood cytology
index) obtained through random periareolar fine needle aspiration (RPFNA).
- Collect subcutaneous abdominal fat aspirations in the 50% subsample of women.
OUTLINE: This is a randomized study. Participants are stratified according to body mass
index (< 30 vs ≥ 30) and RPFNA-consent. All participants will receive a 6-month weight loss
intervention (prescribed weight loss goal of 10% of initial body weight) followed by 6
months' maintenance therapy.
Baseline, 6-, and 12-month measurements will include weight, BMI, waist and hip
circumference, serum 25-hydroxyvitamin D, fasting blood samples, and questionnaires on
details of diet especially items containing vitamin D, physical activity levels, sun
exposure including clothing and sunscreen habits, dietary supplement and vitamin use, and
medications.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |